PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 19926952-9 2009 He underwent chemotherapy (rituximab-THP-COP) and achieved complete remission again. pirarubicin 37-40 caspase recruitment domain family member 16 Homo sapiens 41-44 18820913-7 2009 RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP. pirarubicin 55-66 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 115-119 19481330-1 2009 Differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy and quantum calculation based on molecular modeling were applied to investigate the interaction between pirarubicin (THP), an anthracycline antibiotic frequently used in chemotherapy, and zwitterionic distearoylphosphatidylcholine (DSPC) or anionic distearoylphosphatidylglycerol (DSPG). pirarubicin 192-203 uromodulin Homo sapiens 205-208 17687223-1 2007 We report our second patient treated successfully with a new combined chemotherapy regimen of intra-arterial pirarubicin and nedaplatin plus intravenous methotrexate and vincristine for squamous cell carcinoma (SCC) of the bladder. pirarubicin 109-120 serpin family B member 3 Homo sapiens 211-214 19140665-7 2009 Compound 3d shows the most promising properties as it was able to completely reverse Pgp-dependent pirarubicin extrusion at low nanomolar concentration, inhibited ATPase activity at 5 x 10(-9) and increased the cytotoxicity of doxorubicin with a reversal fold (RF) of 36.4 at 3 microM concentration. pirarubicin 99-110 phosphoglycolate phosphatase Homo sapiens 85-88 17671895-0 2007 Evaluation of the effect of SMA-pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice. pirarubicin 32-43 immunoglobulin mu binding protein 2 Mus musculus 28-31 17671895-2 2007 SMA forms stable self-assembled associated micelles with pirarubicin (SMA-pirarubicin), and confers macromolecular characteristics to pirarubicin. pirarubicin 57-68 immunoglobulin mu binding protein 2 Mus musculus 0-3 17671895-2 2007 SMA forms stable self-assembled associated micelles with pirarubicin (SMA-pirarubicin), and confers macromolecular characteristics to pirarubicin. pirarubicin 74-85 immunoglobulin mu binding protein 2 Mus musculus 0-3 17671895-2 2007 SMA forms stable self-assembled associated micelles with pirarubicin (SMA-pirarubicin), and confers macromolecular characteristics to pirarubicin. pirarubicin 74-85 immunoglobulin mu binding protein 2 Mus musculus 70-73 17671895-2 2007 SMA forms stable self-assembled associated micelles with pirarubicin (SMA-pirarubicin), and confers macromolecular characteristics to pirarubicin. pirarubicin 74-85 immunoglobulin mu binding protein 2 Mus musculus 0-3 17671895-2 2007 SMA forms stable self-assembled associated micelles with pirarubicin (SMA-pirarubicin), and confers macromolecular characteristics to pirarubicin. pirarubicin 74-85 immunoglobulin mu binding protein 2 Mus musculus 70-73 17671895-4 2007 Administration of SMA-pirarubicin micelle under HBO can further enhance the delivery of molecular oxygen that facilitates tumor selective generation of ROS, thus augmenting its antitumor potency. pirarubicin 22-33 immunoglobulin mu binding protein 2 Mus musculus 18-21 17671895-5 2007 In this study, we evaluated the efficacy of SMA-pirarubicin micelles either as single drug or in combination with HBO in a mouse metastatic colorectal cancer model. pirarubicin 48-59 immunoglobulin mu binding protein 2 Mus musculus 44-47 17671895-6 2007 At or below the maximum tolerated dose, SMA-pirarubicin remarkably reduced metastatic tumor nodules and it was far more effective than free pirarubicin. pirarubicin 44-55 immunoglobulin mu binding protein 2 Mus musculus 40-43 17611656-7 2007 Up-regulation of LFA-3 and ICAM-1 was also observed in ACHN cells treated with two derivatives of ADR, epirubicin and pirarubicin. pirarubicin 118-129 CD58 molecule Homo sapiens 17-22 17611656-7 2007 Up-regulation of LFA-3 and ICAM-1 was also observed in ACHN cells treated with two derivatives of ADR, epirubicin and pirarubicin. pirarubicin 118-129 intercellular adhesion molecule 1 Homo sapiens 27-33 17351635-4 2007 Although this inhibition is increased by THP administration before puberty and in adults, during puberty THP reduces the tonic inhibition of pyramidal cells in hippocampal region CA1, leading to increased excitability. pirarubicin 105-108 carbonic anhydrase 1 Mus musculus 179-182 17351635-5 2007 This paradoxical effect of THP results from inhibition of alpha4betadelta GABAA receptors. pirarubicin 27-30 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1 Mus musculus 74-79 17351635-8 2007 Therefore, inhibition of alpha4beta2delta GABAA receptors by THP provides a mechanism for the generation of anxiety at puberty. pirarubicin 61-64 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1 Mus musculus 42-47 16903076-9 2006 When Rb1 was administered orally prior to immobilization stress, the THP level in the frontal cortex and cerebellum was significantly lower than that in the stressed animals not given Rbl. pirarubicin 69-72 RB transcriptional corepressor 1 Mus musculus 5-8 17081691-1 2007 The alpha4 subunit of the GABA(A) receptor (GABAR) has relatively low expression in the CNS, but is increased in vivo following 48 h administration of the GABA-modulatory steroid 3alpha-OH-5alpha[beta]-pregnan-20-one (THP or [allo]pregnanolone) to female rats. pirarubicin 218-221 immunoglobulin binding protein 1 Homo sapiens 4-10 17081691-4 2007 In undifferentiated IMR-32 cells, 48 h administration of THP increased alpha4 expression when ambient THP levels were reduced by the 5alpha-reductase blocker 4MA, suggesting that the background steroid milieu affects steroid regulation of this subunit. pirarubicin 57-60 immunoglobulin binding protein 1 Homo sapiens 71-77 17081691-6 2007 In the absence of NGF treatment, combined administration of 17beta-estradiol (E2) plus THP also increased alpha4 expression to a similar extent as THP following NGF treatment. pirarubicin 87-90 immunoglobulin binding protein 1 Homo sapiens 106-112 16984259-6 2006 In culture MMP-21 was upregulated by phorbol myristate acetate in THP-1 cells and by retinoic acid (RA) in U937 cells, and downregulated by transforming growth factor beta 1 (TGF-beta1) in HEL 299 as assessed by Taqman quantitative polymerase chain reaction (PCR). pirarubicin 66-69 matrix metallopeptidase 21 Homo sapiens 11-17 16193334-9 2006 As we have shown in rats, THP withdrawal also resulted in increased expression of the alpha4 subunit in mouse CA1 hippocampus. pirarubicin 26-29 carbonic anhydrase 1 Mus musculus 110-113 16683659-1 2006 AIM: We examined the efficacy and adverse effects of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) or THP-COP (pirarubicin, cyclophosphamide, vincristin, prednisone) in previously untreated old-old and extremely old patients with diffuse large B cell lymphoma (DLBCL). pirarubicin 132-135 caspase recruitment domain family member 16 Homo sapiens 136-139 15990994-10 2005 However, the addition of THP induced fibrosis of synovial tissues, increased cells without nuclei, and diminished fascin-expressing cells. pirarubicin 25-28 fascin actin-bundling protein 1 Homo sapiens 114-120 16110873-8 2005 CONCLUSION: l-THP depresses expression of ICAM-1 and E-selectin induced by LPS, which suggests that I-THP represent a promising candidate to be developed into therapies for the treatment of inflammation. pirarubicin 14-17 intercellular adhesion molecule 1 Homo sapiens 42-48 15957946-2 2005 The common THP ring system was stereoselectively constructed through a SmI(2)-induced reductive cyclization of beta-alkoxy acrylate 5 followed by Mitsunobu inversion, and each chiral center at C-10 was created by Brown"s asymmetric allylation. pirarubicin 11-14 homeobox C10 Homo sapiens 193-197 16110873-8 2005 CONCLUSION: l-THP depresses expression of ICAM-1 and E-selectin induced by LPS, which suggests that I-THP represent a promising candidate to be developed into therapies for the treatment of inflammation. pirarubicin 14-17 selectin E Homo sapiens 53-63 15526202-8 2005 However, THP uptake by CNT2 transfectant was almost the same as that by mock cells, indicating that an unidentified CNT isoform contributes to THP uptake by M5076 cells, this being supported by the differences in transport characteristics of [3H]uridine between M5076 and CNT2-transfected cells. pirarubicin 9-12 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 Mus musculus 23-27 15884115-10 2005 A strong correlation was only found between the level of MRP3 expression and the IC(50) values of etoposide, doxorubicin and pirarubicin (r = 0.86-0.98, P<0.05). pirarubicin 125-136 ATP binding cassette subfamily C member 3 Homo sapiens 57-61 15884115-13 2005 MRP3 was correlated with resistance of CCA cell lines to etoposide, doxorubicin and pirarubicin, whereas other chemotherapeutic drugs showed no association. pirarubicin 84-95 ATP binding cassette subfamily C member 3 Homo sapiens 0-4 15814336-0 2005 Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin"s lymphoma. pirarubicin 89-92 caspase recruitment domain family member 16 Homo sapiens 93-96 15814336-2 2005 In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy. pirarubicin 27-30 caspase recruitment domain family member 16 Homo sapiens 45-48 15814336-2 2005 In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy. pirarubicin 32-43 caspase recruitment domain family member 16 Homo sapiens 45-48 15814336-7 2005 The complete remission rates for the THP-COP, CHOP, and THP-COPE groups were 42.5%, 41.4%, and 48.0%, respectively. pirarubicin 37-40 caspase recruitment domain family member 16 Homo sapiens 41-44 15480457-1 2004 The "naked" anion of (S)-6-methyl delta lactol undergoes efficient oxy-Michael addition to alpha,beta-disubstituted nitro olefins to give the THP* protected Henry products with excellent (95-->98% de) stereocontrol at the beta-position and moderate (up to 3 : 1) stereocontrol at the alpha-position in favour of the syn-diastereoisomer. pirarubicin 142-145 synemin Homo sapiens 319-322 15513513-1 2004 OBJECTIVE: We present the response rate and adverse effects of our regimen of concurrent chemoradiotherapy with pirarubicin (THP) and 5-fluorouracil (5-FU) for oral and maxillary carcinoma. pirarubicin 112-123 uromodulin Homo sapiens 125-128 15009365-6 2004 RESULTS: Treatment of ACHN and Caki-1 human RCC lines with TRAIL, in combination with subtoxic concentrations of epirubicin (EPI) or pirarubicin (THP), enhanced induction of apoptosis and cytotoxicity. pirarubicin 133-144 TNF superfamily member 10 Homo sapiens 59-64 15248924-8 2004 Recurrence after instillation of IFN-alpha combining THP was observed in only 4 cases (12.1%), bladder irritation was found in 4 cases, fatigue in 3 cases, and rash in 1 case as well. pirarubicin 53-56 interferon alpha 1 Homo sapiens 33-42 15248924-10 2004 IFN-alpha plus THP yielded better effect than THP alone (P< 0.05),especially in grade 3 and stage PT1 bladder cancer. pirarubicin 15-18 zinc finger protein 77 Homo sapiens 101-104 15248924-10 2004 IFN-alpha plus THP yielded better effect than THP alone (P< 0.05),especially in grade 3 and stage PT1 bladder cancer. pirarubicin 46-49 interferon alpha 1 Homo sapiens 0-9 15248924-11 2004 CONCLUSIONS: IFN-alpha working in coordination with THP would be an effective remedy to prevent the recurrence of bladder cancer. pirarubicin 52-55 interferon alpha 1 Homo sapiens 13-22 15248924-12 2004 The intravesical IFN-alpha plus THP appears to be more effective against recurrence than THP alone. pirarubicin 89-92 interferon alpha 1 Homo sapiens 17-26 12578859-10 2003 However anti-DC-SIGN antibodies did not block virus binding and transmission to T cells as well in DC as in THP-DC-SIGN transfectants. pirarubicin 108-111 CD209 molecule Homo sapiens 112-119 12897808-0 2003 Functional study of intracellular P-gp- and MRP1-mediated pumping of free cytosolic pirarubicin into acidic organelles in intrinsic resistant SiHa cells. pirarubicin 84-95 phosphoglycolate phosphatase Homo sapiens 34-38 12897808-0 2003 Functional study of intracellular P-gp- and MRP1-mediated pumping of free cytosolic pirarubicin into acidic organelles in intrinsic resistant SiHa cells. pirarubicin 84-95 ATP binding cassette subfamily C member 1 Homo sapiens 44-48 12897808-1 2003 We sought to determine the efficiency of the intracellular functional P-gp- and MRP1-mediated pumping of THP into acidic organelles in SiHa cells and etoposide-resistant SiHa/VP16 cells. pirarubicin 105-108 phosphoglycolate phosphatase Homo sapiens 70-74 12897808-1 2003 We sought to determine the efficiency of the intracellular functional P-gp- and MRP1-mediated pumping of THP into acidic organelles in SiHa cells and etoposide-resistant SiHa/VP16 cells. pirarubicin 105-108 ATP binding cassette subfamily C member 1 Homo sapiens 80-84 12897808-3 2003 The functional studies of both intracellular functional P-gp- and MRP1-mediated pumping were performed by using THP in a conventional spectrofluorometer, and they demonstrated that SiHa and SiHa/VP16 cells are good models to illustrate the functional role of intracellular P-gp and MRP1 in the transport of free cytosolic drug into acidic organelles. pirarubicin 112-115 ATP binding cassette subfamily C member 1 Homo sapiens 66-70 14648210-0 2004 Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin"s lymphoma. pirarubicin 17-20 caspase recruitment domain family member 16 Homo sapiens 21-24 14648210-3 2004 METHODS: A prospective, randomized phase II study with 80 patients (40 receiving CHOP or THP-COP) less than 70 years of age with previously untreated aggressive non-Hodgkin"s lymphoma (NHL). pirarubicin 89-92 caspase recruitment domain family member 16 Homo sapiens 93-96 14648210-6 2004 Complete remission rate was 72.5% (72.5% for CHOP, 72.5% for THP-COP). pirarubicin 61-64 caspase recruitment domain family member 16 Homo sapiens 65-68 15350632-0 2004 The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells. pirarubicin 138-149 ATP binding cassette subfamily C member 1 Homo sapiens 76-117 15110186-4 2004 Studies from our laboratory have also shown that TRAIL-resistant renal cell carcinoma, prostate gland cancer, and bladder cancer cells are sensitized by subtoxic concentrations of chemotherapeutic drugs including doxorubicin, epirubicin, pirarubicin, and cisplatin. pirarubicin 238-249 TNF superfamily member 10 Homo sapiens 49-54 12938276-7 2003 We performed dose-escalating chemotherapy: A half dose of THP-COP (pirarubicin, cyclophosphamide, vincristine) was given at the start in October 2001, 60% THP-COP as the next cycle, 80% THP-COP as the 3rd cycle and thereafter. pirarubicin 58-61 caspase recruitment domain family member 16 Homo sapiens 62-65 12931565-8 2003 After chemotherapy with the THP-COP regimen, the patient"s liver dysfunction improved rapidly, but she died from bacterial peritonitis due to perforation of a recurrent duodenal ulcer. pirarubicin 28-31 caspase recruitment domain family member 16 Homo sapiens 32-35 12792700-13 2003 THP showed an average IO-PTH decrease of 91.9%, and cure was obtained in 87.5% of patients. pirarubicin 0-3 parathyroid hormone Homo sapiens 25-28 12679883-9 2003 In the cells, formycin B, a representative CNT2 ligand, had cis-inhibitory and trans-stimulatory effects on THP uptake. pirarubicin 108-111 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 Mus musculus 43-47 12890523-9 2003 These data suggest that (i) transient increase of neurosteroid biosynthesis may contribute to stress hyporesponsiveness during early infancy; (ii) gonadal steroids regulate 3 alpha-HSD expression in the hippocampus in a sex-specific mode; (iii) physiological sex steroid secretions in females may mask behavioral consequences of adverse early life events, and (iv) concomitant treatment with the neurosteroid THP counteracts behavioral and endocrine dysregulation induced by neonatal stress in both genders. pirarubicin 409-412 aldo-keto reductase family 1, member C14 Rattus norvegicus 173-184 11791127-0 2001 Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. pirarubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 11956588-8 2002 Synergistic cytotoxicity was also obtained even when the exposure time was shortened from 24 to 8 or 2 h. A similar effect was achieved with TRAIL in combination with epirubicin, pirarubicin, or amrubicin. pirarubicin 179-190 TNF superfamily member 10 Homo sapiens 141-146 11911309-7 2001 Depending on the morphological type, spindle cell sarcomas were sensitive to THP, which showed significantly higher inhibition rates than CDDP, IFOS, or VP-16. pirarubicin 77-80 host cell factor C1 Homo sapiens 153-158 11579501-4 2001 The THP-COP regimen was not effective and the patient died of severe metabolic acidosis 2 months later. pirarubicin 4-7 caspase recruitment domain family member 16 Homo sapiens 8-11 11408917-9 2001 Epirubicin and pirarubicin, compounds closely related to ADR, also respectively enhanced 4.2-fold (p = 0.0052) and 2.8-fold (p = 0.0147) caspase-3 activity in ACHN cells. pirarubicin 15-26 caspase 3 Homo sapiens 137-146 11523171-0 2001 [CHF arising after low dose THP-COP chemotherapy in an elderly patient with malignant lymphoma]. pirarubicin 28-31 caspase recruitment domain family member 16 Homo sapiens 32-35 11523171-5 2001 We started chemotherapy according to the low-dose THP-COP protocol (pirarubicin, cyclophosphamide, vincristine and prednisolone) on the 31st hospital day. pirarubicin 50-53 caspase recruitment domain family member 16 Homo sapiens 54-57 11523171-12 2001 When the THP-COP protocol is indicated in elderly patients, cardiotoxicity should be monitored even if the total dose of pirarubicin is very low. pirarubicin 9-12 caspase recruitment domain family member 16 Homo sapiens 13-16 12489924-0 2002 Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. pirarubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 12489924-0 2002 Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. pirarubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 12489924-4 2002 We used spectrofluorometric methods to determine the kinetics of the uptake and P-gp-mediated efflux of THP in the different selected MDR K562 sublines. pirarubicin 104-107 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 12489924-10 2002 The P-gp-mediated efflux of THP and an accumulation of THP in acidic organelles confer an advantage for MDR cells in surviving prolonged exposure to cytotoxic agents and giving rise to high degrees of resistance. pirarubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10949401-0 2000 Effect of adjuvant chemotherapy using pirarubicin, cisplatin, and etoposide (PEP) for stage IVB endometrial carcinoma: a case report. pirarubicin 38-49 progestagen associated endometrial protein Homo sapiens 77-80 11201151-5 2000 Treatment with the THP-COP regimen achieved clinical remission except for mild splenomegaly, but relapse of LAHS was confirmed two years after diagnosis. pirarubicin 19-22 caspase recruitment domain family member 16 Homo sapiens 23-26 10729360-8 2000 We now examined the effect of PAK-104P on Pgp-and MRP1-mediated efflux of three anthracyclines, daunorubicin, pirarubicin, hydroxydoxorubicin and of calcein acetoxymethyl ester and calcein. pirarubicin 110-121 ATP binding cassette subfamily C member 1 Homo sapiens 50-54 10729360-11 2000 PAK-104P also non-competitively inhibits the MRP(1)-mediated efflux of daunorubicin, pirarubicin, hydroxyrubicin, calcein acetoxymethyl ester and calcein. pirarubicin 85-96 ATP binding cassette subfamily C member 1 Homo sapiens 45-50 10949401-5 2000 She showed a remarkable response to a PEP (pirarubicin, etoposide, cisplatin) regimen and has survived without disease over 8 years. pirarubicin 43-54 progestagen associated endometrial protein Homo sapiens 38-41 10418960-6 1999 For this purpose, cells were irradiated in the presence of VP* and various concentrations of either verapamil or of one of the anthracyclines and then the P-gp functionality was checked by its ability to pump pirarubicin. pirarubicin 209-220 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 9615748-0 1998 Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues. pirarubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 9837770-8 1998 LPL increased binding and uptake of the mildly oxidized (compared to nonoxidized) LDL by THP-I monocyte-derived macrophages. pirarubicin 89-92 lipoprotein lipase Homo sapiens 0-3 9744556-7 1998 At pH 7.2, 50% of the P-glycoprotein-mediated efflux of daunorubicin and idarubicin was inhibited by about 40 +/- 10 microM vinblastine and that of pirarubicin by 10 +/- 2 microM vinblastine. pirarubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 9744556-11 1998 A detailed kinetics analysis of the P-glycoprotein-mediated efflux of pirarubicin in the presence of vinblastine indicates a non competitive inhibition with K(I) = 12 +/- 2 microM. pirarubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 9647245-7 1998 After the peak of the response, the Thp frequency decreased only about twofold per CD4+ T cell to approximately 1/1200 and remained stable into long term memory. pirarubicin 36-39 CD4 molecule Homo sapiens 83-86 9615748-10 1998 Pgp was expressed in 23.5% (12/51) specimens and the efficacy of anthracyclines was reduced in Pgp-positive breast cancer tissues, although this reduction was low in THP with a statistically significant difference when comparing with DXR and EPIR. pirarubicin 166-169 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 8818396-10 1996 On the contrary, 3 alpha-hydroxysteroid dehydrogenase, the enzyme which converts DHP into 5 alpha-pregnane-3 alpha-ol-20-one (THP), appears to be present mainly in type-1 astrocytes; much lower levels of this enzyme are present in neurons and in type-2 astrocytes. pirarubicin 126-129 aldo-keto reductase family 1, member C14 Rattus norvegicus 17-53 9369412-8 1997 Despite the administration of granulocyte colony-stimulating factor (G-CSF), however, the white blood cell count decreased in many patients, suggesting the necessity for further study of this regimen to modify the dose of THP. pirarubicin 222-225 colony stimulating factor 3 Homo sapiens 69-74 9334240-3 1997 To clarify this, we purified natural hIL-18 from the cytosolic extract of monocytic THP.1 cells. pirarubicin 84-87 interleukin 18 Homo sapiens 37-43 8946427-1 1996 The neurosteroid tetrahydroprogesterone (5 alpha-pregnan-3 alpha-ol-20-one, allopregnanolone, THP), has been previously shown to counteract the anxiogenic effects of corticotropin-releasing hormone (CRH) and to interfere with noradrenergic and corticosteroid-mediated regulation of CRH release and gene transcription. pirarubicin 94-97 corticotropin releasing hormone Rattus norvegicus 166-197 8946427-1 1996 The neurosteroid tetrahydroprogesterone (5 alpha-pregnan-3 alpha-ol-20-one, allopregnanolone, THP), has been previously shown to counteract the anxiogenic effects of corticotropin-releasing hormone (CRH) and to interfere with noradrenergic and corticosteroid-mediated regulation of CRH release and gene transcription. pirarubicin 94-97 corticotropin releasing hormone Rattus norvegicus 199-202 8946427-1 1996 The neurosteroid tetrahydroprogesterone (5 alpha-pregnan-3 alpha-ol-20-one, allopregnanolone, THP), has been previously shown to counteract the anxiogenic effects of corticotropin-releasing hormone (CRH) and to interfere with noradrenergic and corticosteroid-mediated regulation of CRH release and gene transcription. pirarubicin 94-97 corticotropin releasing hormone Rattus norvegicus 282-285 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. pirarubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. pirarubicin 47-58 ATP binding cassette subfamily C member 1 Homo sapiens 142-145 9350248-4 1997 From the above experience, it is concluded that the MTD of pirarubicin seems to be 1,500 mg/body or 1,100 mg/m2. pirarubicin 59-70 metallothionein 1E Homo sapiens 52-55 9006749-0 1996 Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin"s lymphoma treated with a pirarubicin-combination chemotherapy regimen. pirarubicin 137-148 colony stimulating factor 3 Homo sapiens 10-47 8818396-10 1996 On the contrary, 3 alpha-hydroxysteroid dehydrogenase, the enzyme which converts DHP into 5 alpha-pregnane-3 alpha-ol-20-one (THP), appears to be present mainly in type-1 astrocytes; much lower levels of this enzyme are present in neurons and in type-2 astrocytes. pirarubicin 126-129 dihydropyrimidinase Rattus norvegicus 81-84 7579561-3 1995 The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells. pirarubicin 93-107 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 148-151 8678321-4 1995 Large pore C18 or C4 reversed-phase HPLC gave broad peaks, resulting in poor resolution of the desired THP from synthetic impurities. pirarubicin 103-106 Bardet-Biedl syndrome 9 Homo sapiens 11-14 7579561-3 1995 The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells. pirarubicin 93-96 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 148-151 7497603-4 1995 The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2. pirarubicin 33-40 interleukin 1 receptor like 1 Homo sapiens 149-159 7541373-1 1995 The ability of a small molecule, 2-methyl,4-carboxy,5-hydroxy-3,4,5,6-tetrahydropyrimidine (THP(A)), which accumulates intracellularly in various streptomyces, to inhibit the interaction of Tat peptide (R52) with TAR RNA is presented. pirarubicin 92-95 RNA binding motif protein 8A Homo sapiens 213-216 7541373-5 1995 A model for THP(A)-TAR interaction, analogous to the arginine guanidinum group-TAR interaction, is presented. pirarubicin 12-15 RNA binding motif protein 8A Homo sapiens 19-22 7541373-5 1995 A model for THP(A)-TAR interaction, analogous to the arginine guanidinum group-TAR interaction, is presented. pirarubicin 12-15 RNA binding motif protein 8A Homo sapiens 79-82 7541373-6 1995 The relatively high uptake of THP(A) by mammalian cells warrants in vivo Tat/TAR inhibition studies. pirarubicin 30-33 RNA binding motif protein 8A Homo sapiens 77-80 7497603-4 1995 The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2. pirarubicin 33-40 interleukin 1 receptor like 1 Homo sapiens 204-214 8002636-2 1994 More recently, PTP chemotherapy added to CP chemotherapy with THP-adriamycin (THP-ADM) was employed. pirarubicin 78-85 protein tyrosine phosphatase receptor type U Homo sapiens 15-18 7944496-0 1994 [A case of hepatoblastoma using intraarterial hepatic chemotherapy with THP-ADR]. pirarubicin 72-75 aldo-keto reductase family 1 member B Homo sapiens 76-79 8205473-6 1994 On the contrary, the 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD), the enzyme which converts DHP into THP, appears to be mainly present in type-1 astrocytes; much lower levels of this enzyme are present in neurons and in type-2 astrocytes. pirarubicin 108-111 aldo-keto reductase family 1 member C3 Homo sapiens 21-57 8205473-6 1994 On the contrary, the 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD), the enzyme which converts DHP into THP, appears to be mainly present in type-1 astrocytes; much lower levels of this enzyme are present in neurons and in type-2 astrocytes. pirarubicin 108-111 aldo-keto reductase family 1 member C3 Homo sapiens 59-70 8205473-6 1994 On the contrary, the 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD), the enzyme which converts DHP into THP, appears to be mainly present in type-1 astrocytes; much lower levels of this enzyme are present in neurons and in type-2 astrocytes. pirarubicin 108-111 dihydropyrimidine dehydrogenase Homo sapiens 99-102 8311500-2 1994 Eight course of CTF (cyclophosphamide, THP-adriamycin, 5-fluorouracil) and subsequent 4"-epi-adriamycin were performed for locally advanced breast cancer and multiple bone metastases, but the ulcerated breast cancer enlarged. pirarubicin 39-53 nuclear factor I C Homo sapiens 16-19 1353119-3 1992 The KK47/ADM exhibited cross-resistance to doxorubicin derivatives (pirarubicin, epirubicin), vinca alkaloids (vinblastine, vincristine) and etoposide, but not to cisplatin, carboplatin, mitomycin C, peplomycin and methotrexate. pirarubicin 68-79 adrenomedullin Homo sapiens 9-12 7904185-0 1994 Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. pirarubicin 66-80 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 7505687-1 1993 Doxorubicin, pirarubicin, and FAD-104, but not aclarubicin or MX 2, flattened the morphology of NIH3T3 cells that had been transformed by human H-ras and K-ras. pirarubicin 13-24 HRas proto-oncogene, GTPase Homo sapiens 144-149 7505687-1 1993 Doxorubicin, pirarubicin, and FAD-104, but not aclarubicin or MX 2, flattened the morphology of NIH3T3 cells that had been transformed by human H-ras and K-ras. pirarubicin 13-24 KRAS proto-oncogene, GTPase Homo sapiens 154-159 8233640-11 1993 Bactericidal serum titers at the same time against the patients own strain and an E. coli TEM-1 hyperproducer strain (MIC 4,096 mg/l for ampicillin and 0.5 mg/l for CPD) showed a median value of 1/8 against patients strains and 1/2 against the THP strain. pirarubicin 244-247 hypothetical protein Escherichia coli 90-95 1524040-2 1992 An initial dose of 30 mg/m2 of pirarubicin (THP) every 3 weeks was given intravenously. pirarubicin 31-42 uromodulin Homo sapiens 44-47 1872619-0 1991 [Tissue levels of pirarubicin (THP) in dogs following intra-arterial infusion]. pirarubicin 18-29 uromodulin Canis lupus familiaris 31-34 1523998-4 1992 THP instillation was more effective against multiple tumors than a single tumor, stage Ta than T1 and grade G1 than G2 and G3. pirarubicin 0-3 interleukin 1 receptor like 1 Homo sapiens 95-125 1872619-1 1991 The blood and tissue levels of pirarubicin (THP) were studied in dogs by HPLC analysis. pirarubicin 31-42 uromodulin Canis lupus familiaris 44-47 2300381-0 1990 Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin"s lymphoma. pirarubicin 30-41 uromodulin Homo sapiens 43-46 2224762-10 1990 Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. pirarubicin 49-60 CD5 molecule Homo sapiens 68-95 2224762-10 1990 Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. pirarubicin 49-60 CD5 molecule Homo sapiens 68-71 2300381-0 1990 Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin"s lymphoma. pirarubicin 30-41 uromodulin Homo sapiens 102-105 33819623-0 2021 Targeting Breast Cancer Using Pirarubicin-Loaded Vasoactive Intestinal Peptide Grafted Sterically Stabilized Micelles. pirarubicin 30-41 vasoactive intestinal peptide Homo sapiens 49-78 34843906-6 2022 Subsequent experiments further confirmed that ornithine decarboxylase (ODC1) and spermidine synthase (SRM), the key enzymes involved in the synthesis of these compounds, also showed a stable low expression in T24/THP. pirarubicin 213-216 ornithine decarboxylase 1 Homo sapiens 46-69 24932293-7 2014 Following treatment with CTX and THP, the protein expression of CXCR4 in LAN-5 and SK-N-SH cells was significantly decreased (P<0.05). pirarubicin 33-36 C-X-C motif chemokine receptor 4 Homo sapiens 64-69 24932293-8 2014 The expression of Foxp3 in LAN-5 cells was also significantly downregulated by CTX and THP treatment (P<0.05). pirarubicin 87-90 forkhead box P3 Homo sapiens 18-23 34843906-6 2022 Subsequent experiments further confirmed that ornithine decarboxylase (ODC1) and spermidine synthase (SRM), the key enzymes involved in the synthesis of these compounds, also showed a stable low expression in T24/THP. pirarubicin 213-216 ornithine decarboxylase 1 Homo sapiens 71-75 34843906-6 2022 Subsequent experiments further confirmed that ornithine decarboxylase (ODC1) and spermidine synthase (SRM), the key enzymes involved in the synthesis of these compounds, also showed a stable low expression in T24/THP. pirarubicin 213-216 spermidine synthase Homo sapiens 81-100 34843906-6 2022 Subsequent experiments further confirmed that ornithine decarboxylase (ODC1) and spermidine synthase (SRM), the key enzymes involved in the synthesis of these compounds, also showed a stable low expression in T24/THP. pirarubicin 213-216 spermidine synthase Homo sapiens 102-105 34843906-10 2022 According to this line of thought, we found that c-MYC was also down-regulated in T24/THP and its content could be significantly affected by drug administration. pirarubicin 86-89 MYC proto-oncogene, bHLH transcription factor Homo sapiens 49-54 34843906-11 2022 In addition, c-MYC could not only regulate the expression levels of ODC1 and SRM but also influence drug resistance in T24/THP. pirarubicin 123-126 MYC proto-oncogene, bHLH transcription factor Homo sapiens 13-18 34843906-11 2022 In addition, c-MYC could not only regulate the expression levels of ODC1 and SRM but also influence drug resistance in T24/THP. pirarubicin 123-126 ornithine decarboxylase 1 Homo sapiens 68-72 34843906-11 2022 In addition, c-MYC could not only regulate the expression levels of ODC1 and SRM but also influence drug resistance in T24/THP. pirarubicin 123-126 spermidine synthase Homo sapiens 77-80 34476509-0 2021 Gallic acid enhances pirarubicin-induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P-glycoprotein inhibition. pirarubicin 21-32 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 34812269-0 2021 Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E. pirarubicin 57-68 eukaryotic translation initiation factor 4E Homo sapiens 111-116 34812269-3 2021 Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). pirarubicin 181-192 eukaryotic translation initiation factor 4E Homo sapiens 87-130 34812269-3 2021 Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). pirarubicin 181-192 eukaryotic translation initiation factor 4E Homo sapiens 132-137 34812269-3 2021 Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). pirarubicin 194-197 eukaryotic translation initiation factor 4E Homo sapiens 87-130 34812269-3 2021 Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). pirarubicin 194-197 eukaryotic translation initiation factor 4E Homo sapiens 132-137 34812269-8 2021 Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP. pirarubicin 169-172 eukaryotic translation initiation factor 4E Homo sapiens 14-19 34812269-9 2021 These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP. pirarubicin 53-56 eukaryotic translation initiation factor 4E Homo sapiens 116-121 34812269-9 2021 These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP. pirarubicin 257-260 eukaryotic translation initiation factor 4E Homo sapiens 116-121 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 156-167 albumin Mus musculus 216-223 34490125-14 2021 Conclusions: THP was still the optimal first-line treatment for metastatic HER2+ BC. pirarubicin 13-16 erb-b2 receptor tyrosine kinase 2 Homo sapiens 75-79 34093525-5 2021 This effect was very pronounced in Thp-1 cells exposed to bacterial purified lysates or pure ADP-heptose, in the absence of other bacterial MAMPs, and was significantly reduced upon TIFA knock-down. pirarubicin 35-38 TRAF interacting protein with forkhead associated domain Homo sapiens 182-186 35531701-11 2022 Meanwhile, THP promoted the change of LPS-induced BV2 microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, suppressed the activation of the p38 MAPK signaling pathway, decreased the expression levels of inflammatory factors NO, IL-1beta, IL-6, and TNF-alpha, and increased the expression level of anti-inflammatory factor IL-10. pirarubicin 11-14 interleukin 1 alpha Rattus norvegicus 263-271 35531701-11 2022 Meanwhile, THP promoted the change of LPS-induced BV2 microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, suppressed the activation of the p38 MAPK signaling pathway, decreased the expression levels of inflammatory factors NO, IL-1beta, IL-6, and TNF-alpha, and increased the expression level of anti-inflammatory factor IL-10. pirarubicin 11-14 interleukin 6 Rattus norvegicus 273-277 35531701-11 2022 Meanwhile, THP promoted the change of LPS-induced BV2 microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, suppressed the activation of the p38 MAPK signaling pathway, decreased the expression levels of inflammatory factors NO, IL-1beta, IL-6, and TNF-alpha, and increased the expression level of anti-inflammatory factor IL-10. pirarubicin 11-14 tumor necrosis factor Rattus norvegicus 283-292 35531701-11 2022 Meanwhile, THP promoted the change of LPS-induced BV2 microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, suppressed the activation of the p38 MAPK signaling pathway, decreased the expression levels of inflammatory factors NO, IL-1beta, IL-6, and TNF-alpha, and increased the expression level of anti-inflammatory factor IL-10. pirarubicin 11-14 interleukin 10 Rattus norvegicus 357-362 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 156-167 secreted acidic cysteine rich glycoprotein Mus musculus 343-348 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 156-167 macrophage scavenger receptor 1 Mus musculus 354-374 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 156-167 macrophage scavenger receptor 1 Mus musculus 376-380 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 169-172 albumin Mus musculus 216-223 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 169-172 secreted acidic cysteine rich glycoprotein Mus musculus 343-348 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 169-172 macrophage scavenger receptor 1 Mus musculus 354-374 35344323-2 2022 To overcome the common limitations of TAMs-targeted delivery systems, such as off-target toxicity, high cost, and transformation probability, we fabricated pirarubicin (THP)-loaded palmitic acid modified human serum albumin nanoparticles (THP-PSA NPs) for dual-targeting of tumor cells and TAMs via acidic secretory proteins rich in cysteine (SPARC) and scavenger receptor-A (SR-A), respectively. pirarubicin 169-172 macrophage scavenger receptor 1 Mus musculus 376-380 35091545-4 2022 Our results showed that TFG-deficient THP-1 macrophages exhibit higher mitochondrial ROS production. pirarubicin 38-41 trafficking from ER to golgi regulator Homo sapiens 24-27 35149961-4 2022 Findings indicate nearly one-quarter of the PSS workforce continues to need access to technology and one-third need training in the delivery of ThPS. pirarubicin 144-148 PSS Homo sapiens 44-47 35149961-5 2022 Perceptions of the important, critical, and most frequently used competencies for the delivery of ThPS were rated similarly by PSS and managers/supervisors. pirarubicin 98-102 PSS Homo sapiens 127-130 35149961-6 2022 The broad implementation of effective ThPS requires additional resources and training for the PSS workforce. pirarubicin 38-42 PSS Homo sapiens 94-97 34935899-0 2022 Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway. pirarubicin 31-42 heat shock protein family A (Hsp70) member 5 Homo sapiens 16-21 34935899-0 2022 Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway. pirarubicin 31-42 AKT serine/threonine kinase 1 Homo sapiens 127-130 34935899-0 2022 Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway. pirarubicin 31-42 mechanistic target of rapamycin kinase Homo sapiens 131-135 34935899-13 2022 Therefore, the mechanism of pirarubicin resistance might involve the miR-495-3p/GRP78/Akt axis, which would provide a possible strategy for treating TNBC. pirarubicin 28-39 heat shock protein family A (Hsp70) member 5 Homo sapiens 80-85 34935899-13 2022 Therefore, the mechanism of pirarubicin resistance might involve the miR-495-3p/GRP78/Akt axis, which would provide a possible strategy for treating TNBC. pirarubicin 28-39 AKT serine/threonine kinase 1 Homo sapiens 86-89 35038825-1 2022 Purpose: Trastuzumab has markedly improved the survival outcomes of patients with HER2-positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. pirarubicin 199-202 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-136 35038825-1 2022 Purpose: Trastuzumab has markedly improved the survival outcomes of patients with HER2-positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. pirarubicin 199-202 erb-b2 receptor tyrosine kinase 2 Homo sapiens 238-242 35038825-3 2022 Materials and Methods: Between August 2008 and October 2020, we identified 228 HER2-positive MBC patients who received THP as a first-line palliative chemotherapy. pirarubicin 119-122 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-83 3463778-9 1986 The order for K21 and K31 was ACR greater than THP greater than ADR. pirarubicin 47-50 keratin 31 Homo sapiens 22-25 2786120-4 1989 Peritoneal macrophages of THP-ADM-treated mice have an in vitro cytostatic activity towards P815 tumor cells higher than normal cells and when stimulated with LPS they secrete more IL-1, an important effector of the immune response. pirarubicin 26-33 interleukin 1 complex Mus musculus 181-185 2960461-5 1987 In S-Ag-induced EAU many more ThS accumulated in the eye than ThP. pirarubicin 62-65 S-antigen visual arrestin Rattus norvegicus 3-7 3463778-11 1986 The order of magnitude for V2 and V3 was THP greater than ADR greater than ACR. pirarubicin 41-44 T cell receptor gamma variable 9 Homo sapiens 27-36 33741648-5 2021 Patients underwent evaluation with PET/CT 60 minutes following intravenous administration of 160+-30 MBq of 68Ga-THP PSMA. pirarubicin 113-116 folate hydrolase 1 Homo sapiens 117-121 3712757-4 1986 At a dose of 25.0 mg/kg or 50.0 mg/kg, THP caused moderate to remarkable alterations in ECG like a widening of PR and PRc interval, A-V block, ST segment depression and T wave flattening. pirarubicin 39-42 PPARG related coactivator 1 Homo sapiens 118-121 3712757-14 1986 Widening of PR and PRc interval, elevation of R and S wave amplitude, and reduction of T wave amplitude were observed at a daily dose of 1.0 mg/kg of THP. pirarubicin 150-153 PPARG related coactivator 1 Homo sapiens 19-22 33481270-6 2021 Coculture of arsenite-treated, THP-M with LX-2 cells induced alpha-SMA and collagen I in the LX-2 cells and resulted in the activation of these cells. pirarubicin 31-34 actin alpha 1, skeletal muscle Homo sapiens 61-70 33481270-7 2021 Downregulation of miR-21 in THP-M inhibited arsenite-induced M2 polarization and activation of LX-2 cells, but cotransfection with PTEN siRNA or a miR-21 inhibitor reversed this inhibition. pirarubicin 28-31 microRNA 21 Homo sapiens 18-24 33864237-4 2021 THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisone) is sometimes used for elderly patients with non-Hodgkin"s lymphoma in Japan. pirarubicin 9-20 caspase recruitment domain family member 16 Homo sapiens 4-7 33864237-7 2021 The median age was 65 years in the CHOP group and 75 years in the THP-COP group. pirarubicin 66-69 caspase recruitment domain family member 16 Homo sapiens 70-73 33864237-8 2021 The probability of 3-year overall survival (OS) was 49.0% in the CHOP group and 44.9% in the THP-COP group. pirarubicin 93-96 caspase recruitment domain family member 16 Homo sapiens 97-100 33864237-10 2021 Although our study was limited by its retrospective nature, it showed that clinical outcomes with the THP-COP regimen were comparable to those with the CHOP regimen in PTCL-NOS and AITL. pirarubicin 102-105 caspase recruitment domain family member 16 Homo sapiens 106-109 33741648-7 2021 A change in management was reported when the predefined clinical management of the patient altered as a result of 68Ga-THP PSMA PET/CT findings. pirarubicin 119-122 folate hydrolase 1 Homo sapiens 123-127 33741648-9 2021 Two patients had Treatment Emergent AEs attributed to 68Ga-THP-PSMA (pruritus in one patient and intravenous catheter site rash in another). pirarubicin 59-62 folate hydrolase 1 Homo sapiens 63-67 33741648-10 2021 Management change secondary to PET/CT occurred in 42.9% of all patients; 30% in Group A, 42.9% in Group B and 75% in Group C. Conclusion: 68Ga-THP PSMA was safe to use with no serious AE and no AE resulting in withdrawal from the study. pirarubicin 143-146 folate hydrolase 1 Homo sapiens 147-151 33741648-12 2021 These data form the basis of a planned Phase III study of 68Ga-THP PSMA in patients with prostate cancer. pirarubicin 63-66 folate hydrolase 1 Homo sapiens 67-71 33552025-10 2020 Consistent with this mechanism, inhibition of autophagolysosome maturation with bafilomycin A1 abrogated the ability of THP-PKR macrophages to limit replication of Mtb, whereas pharmacological activation of autophagy enhanced the anti-mycobacterial effect of PKR overexpression. pirarubicin 120-123 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 124-127 33552025-10 2020 Consistent with this mechanism, inhibition of autophagolysosome maturation with bafilomycin A1 abrogated the ability of THP-PKR macrophages to limit replication of Mtb, whereas pharmacological activation of autophagy enhanced the anti-mycobacterial effect of PKR overexpression. pirarubicin 120-123 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 259-262 32896532-9 2020 In particular, 7.5 mumol/L THP remarkably promoted RCF autophagy by upregulating the levels of Beclin 1, Atg 5/12 conjugate, and LC3B, whereas, 15 mumol/L THP significantly triggered a cascade of mitochondrial-associated RCF apoptosis. pirarubicin 27-30 beclin-1 Oryctolagus cuniculus 95-103 33162208-8 2021 Arsenite-treated THP-M and BMDMs co-cultured with MRC-5 cells or primary lung fibroblasts (PLFs) elevated levels of p-SMAD2/3, SMAD4, alpha-SMA, and collagen I in lung fibroblasts and resulted in the activation of lung fibroblasts. pirarubicin 17-20 SMAD family member 2 Homo sapiens 118-125 33396604-0 2020 Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin. pirarubicin 84-95 albumin Homo sapiens 56-69 32864822-0 2021 Rutin treats myocardial damage caused by pirarubicin via regulating miR-22-5p-regulated RAP1/ERK signaling pathway. pirarubicin 41-52 microRNA 22 Rattus norvegicus 68-74 32864822-0 2021 Rutin treats myocardial damage caused by pirarubicin via regulating miR-22-5p-regulated RAP1/ERK signaling pathway. pirarubicin 41-52 Eph receptor B1 Rattus norvegicus 93-96 32864822-3 2021 In this study, we developed an microRNA (miRNA) chip by replicating the rat model of THP-induced myocardial injury and identified miR-22-5p and the RAP1-member of RAS oncogene family/extracellular regulated protein kinases (RAP1/ERK) signaling pathway as an object of study. pirarubicin 85-88 Eph receptor B1 Rattus norvegicus 229-232 32864822-5 2021 THP also reduces the expression of miR-22-5p (P < .01) and increases the levels of RAP1/ERK signaling pathway-related proteins (P < .01, P < .05). pirarubicin 0-3 microRNA 22 Rattus norvegicus 35-41 32864822-5 2021 THP also reduces the expression of miR-22-5p (P < .01) and increases the levels of RAP1/ERK signaling pathway-related proteins (P < .01, P < .05). pirarubicin 0-3 Eph receptor B1 Rattus norvegicus 88-91 32864822-9 2021 Our results indicate that RUT treats THP-induced myocardial damage, which may be achieved by upregulating miR-22-5p, causing changes in its target gene Rap1a and the RAP1/ERK pathway. pirarubicin 37-40 microRNA 22 Rattus norvegicus 106-112 32864822-9 2021 Our results indicate that RUT treats THP-induced myocardial damage, which may be achieved by upregulating miR-22-5p, causing changes in its target gene Rap1a and the RAP1/ERK pathway. pirarubicin 37-40 RAP1A, member of RAS oncogene family Rattus norvegicus 152-157 32864822-9 2021 Our results indicate that RUT treats THP-induced myocardial damage, which may be achieved by upregulating miR-22-5p, causing changes in its target gene Rap1a and the RAP1/ERK pathway. pirarubicin 37-40 Eph receptor B1 Rattus norvegicus 171-174 33447559-10 2020 Conclusions: These results suggest that both TCbHP and THP regimens may be useful neoadjuvant treatments for high-risk early or locally advanced HER2-positive breast cancer. pirarubicin 55-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 32896532-9 2020 In particular, 7.5 mumol/L THP remarkably promoted RCF autophagy by upregulating the levels of Beclin 1, Atg 5/12 conjugate, and LC3B, whereas, 15 mumol/L THP significantly triggered a cascade of mitochondrial-associated RCF apoptosis. pirarubicin 27-30 autophagy protein 5 Oryctolagus cuniculus 105-113 33065796-0 2020 Qishen Huanwu capsule reduces pirarubicin-induced cardiotoxicity in rats by activating the PI3K/Akt/mTOR pathway. pirarubicin 30-41 AKT serine/threonine kinase 1 Rattus norvegicus 96-99 32723846-9 2020 Moreover, the co-administration of OCT1/3 inhibitors (levo-tetrahydropalmatine, THP) decreased the concentration of DHC in the mouse heart. pirarubicin 80-83 solute carrier family 22 (organic cation transporter), member 1 Mus musculus 35-41 32723846-14 2020 This ability, hampered by selective inhibitors (THP, an inhibitor of OCT1/3), causes nearly 40% reduction in exposure of the heart to dehydrocorydaline. pirarubicin 48-51 solute carrier family 22 (organic cation transporter), member 3 Mus musculus 69-75 33065796-12 2020 In addition, compared with the control group, the THP group had significantly higher LC3 protein expression, a significantly higher LC3-II/LC3-I ratio (P<0.05), and significantly lower p-PI3K, p-Akt, and p-mTOR (P<0.05). pirarubicin 50-53 microtubule associated protein 1 light chain 3 alpha Homo sapiens 85-88 33065796-12 2020 In addition, compared with the control group, the THP group had significantly higher LC3 protein expression, a significantly higher LC3-II/LC3-I ratio (P<0.05), and significantly lower p-PI3K, p-Akt, and p-mTOR (P<0.05). pirarubicin 50-53 microtubule associated protein 1 light chain 3 alpha Homo sapiens 132-135 33065796-0 2020 Qishen Huanwu capsule reduces pirarubicin-induced cardiotoxicity in rats by activating the PI3K/Akt/mTOR pathway. pirarubicin 30-41 mechanistic target of rapamycin kinase Rattus norvegicus 100-104 33065796-12 2020 In addition, compared with the control group, the THP group had significantly higher LC3 protein expression, a significantly higher LC3-II/LC3-I ratio (P<0.05), and significantly lower p-PI3K, p-Akt, and p-mTOR (P<0.05). pirarubicin 50-53 microtubule associated protein 1 light chain 3 alpha Homo sapiens 132-135 33065796-12 2020 In addition, compared with the control group, the THP group had significantly higher LC3 protein expression, a significantly higher LC3-II/LC3-I ratio (P<0.05), and significantly lower p-PI3K, p-Akt, and p-mTOR (P<0.05). pirarubicin 50-53 AKT serine/threonine kinase 1 Homo sapiens 195-198 32786371-6 2021 [68Ga]Ga-THP-Pam shows high stability in human serum. pirarubicin 9-12 peptidylglycine alpha-amidating monooxygenase Homo sapiens 13-16 33065796-12 2020 In addition, compared with the control group, the THP group had significantly higher LC3 protein expression, a significantly higher LC3-II/LC3-I ratio (P<0.05), and significantly lower p-PI3K, p-Akt, and p-mTOR (P<0.05). pirarubicin 50-53 mechanistic target of rapamycin kinase Homo sapiens 206-210 33065796-16 2020 The underlying mechanism was related to the activation of the PI3K/Akt/mTOR pathway and the mitigation of the excessive autophagy of cardiomyocytes caused by THP. pirarubicin 158-161 AKT serine/threonine kinase 1 Rattus norvegicus 67-70 33065796-16 2020 The underlying mechanism was related to the activation of the PI3K/Akt/mTOR pathway and the mitigation of the excessive autophagy of cardiomyocytes caused by THP. pirarubicin 158-161 mechanistic target of rapamycin kinase Rattus norvegicus 71-75 32016695-0 2020 Rutin protects against pirarubicin-induced cardiotoxicity by adjusting microRNA-125b-1-3p-mediated JunD signaling pathway. pirarubicin 23-34 jun D proto-oncogene Mus musculus 99-103 31957170-0 2020 MicroRNA-129-1-3p protects cardiomyocytes from pirarubicin-induced apoptosis by down-regulating the GRIN2D-mediated Ca2+ signalling pathway. pirarubicin 47-58 glutamate ionotropic receptor NMDA type subunit 2D Rattus norvegicus 100-106 31682910-2 2019 Herein, a multifunctional peptide (P51) was developed for programmed delivery of the hydrophobic chemotherapeutic agent pirarubicin. pirarubicin 120-131 tumor protein p63 Homo sapiens 35-38 31682910-7 2019 Self-assembly of P51 and pirarubicin (P51-THP NPs) results into stable spherical nanoparticles in a single step. pirarubicin 25-36 tumor protein p63 Homo sapiens 38-41 31682910-8 2019 We demonstrate that the acid environment, DTT, and MMP-2 stimulated the release of pirarubicin from P51-THP NPs and, more importantly, the efficiency of drug release is markedly increased when all three release triggers are present. pirarubicin 83-94 matrix metallopeptidase 2 Homo sapiens 51-56 31559456-0 2019 Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. pirarubicin 103-114 epidermal growth factor receptor Homo sapiens 0-32 31682910-8 2019 We demonstrate that the acid environment, DTT, and MMP-2 stimulated the release of pirarubicin from P51-THP NPs and, more importantly, the efficiency of drug release is markedly increased when all three release triggers are present. pirarubicin 83-94 tumor protein p63 Homo sapiens 100-103 31559456-11 2019 CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. pirarubicin 46-49 heme oxygenase 1 Homo sapiens 75-79 31559456-0 2019 Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. pirarubicin 103-114 heme oxygenase 1 Homo sapiens 33-49 31559456-11 2019 CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. pirarubicin 46-49 heme oxygenase 1 Homo sapiens 168-172 31559456-1 2019 PURPOSE: To investigate the possibility that the antioxidant stress protein Heme oxygenase-1 (HO-1) is involved in the acquisition of chemoresistance in cisplatin and pirarubicin (CITA) therapy. pirarubicin 167-178 heme oxygenase 1 Homo sapiens 76-92 31559456-11 2019 CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. pirarubicin 46-49 epidermal growth factor receptor Homo sapiens 176-180 31559456-1 2019 PURPOSE: To investigate the possibility that the antioxidant stress protein Heme oxygenase-1 (HO-1) is involved in the acquisition of chemoresistance in cisplatin and pirarubicin (CITA) therapy. pirarubicin 167-178 heme oxygenase 1 Homo sapiens 94-98 31559456-6 2019 RESULTS: HO-1 expression in HepG2 cells was increased by the treatment of cisplatin (CDDP) and pirarubicin (THP) dose-dependently. pirarubicin 95-106 heme oxygenase 1 Homo sapiens 9-13 31559456-6 2019 RESULTS: HO-1 expression in HepG2 cells was increased by the treatment of cisplatin (CDDP) and pirarubicin (THP) dose-dependently. pirarubicin 108-111 heme oxygenase 1 Homo sapiens 9-13 31559456-7 2019 In HO-1 knockdown HepG2 cells, the HO-1 was not expressed and the percentage of trypan blue-positive cells (dead cells) was significantly increased after treatment of CDDP and THP. pirarubicin 176-179 heme oxygenase 1 Homo sapiens 3-7 31559456-9 2019 Combination treatment of EGFR inhibitor with CDDP and THP increased the cytotoxic effect in HepG2 cells. pirarubicin 54-57 epidermal growth factor receptor Homo sapiens 25-29 31649535-0 2019 Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth. pirarubicin 19-30 AKT serine/threonine kinase 1 Homo sapiens 39-42 31649535-2 2019 In this study, we found that pirarubicin (THP), one important chemotherapeutic drug for treating bladder cancer intravesically, dramatically elevated phosphorylations of both Akt and Erk1/2 in addition to inducing DNA damage. pirarubicin 29-40 AKT serine/threonine kinase 1 Homo sapiens 175-178 31649535-2 2019 In this study, we found that pirarubicin (THP), one important chemotherapeutic drug for treating bladder cancer intravesically, dramatically elevated phosphorylations of both Akt and Erk1/2 in addition to inducing DNA damage. pirarubicin 29-40 mitogen-activated protein kinase 3 Homo sapiens 183-189 31138757-0 2019 Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway. pirarubicin 82-93 AKT serine/threonine kinase 1 Homo sapiens 135-138 31138757-0 2019 Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway. pirarubicin 82-93 mechanistic target of rapamycin kinase Homo sapiens 139-143 29512924-6 2018 Molecular mechanisms of PKM2 on THP sensitization were explored by probing p-AMPK and p-STAT3 levels via WB. pirarubicin 32-35 pyruvate kinase M1/2 Homo sapiens 24-28 30924055-6 2019 The kinetic of P-glycoprotein-mediated efflux pirarubicin was used to monitor P-glycoprotein function in multidrug resistant (MDR) cancer cells. pirarubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 30924055-6 2019 The kinetic of P-glycoprotein-mediated efflux pirarubicin was used to monitor P-glycoprotein function in multidrug resistant (MDR) cancer cells. pirarubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 30742936-1 2019 CA1 hippocampal expression of alpha4betadelta GABAA receptors (GABARs) increases at the onset of puberty in female mice, an effect dependent upon the decline in hippocampal levels of the neurosteroid THP (3alpha-OH-5alpha-pregnan-20-one) which occurs at this time. pirarubicin 200-203 carbonic anhydrase 1 Mus musculus 0-3 30742936-7 2019 These results suggest that both the rise in circulating levels of E2 and the decline in hippocampal THP levels at the onset of puberty trigger maximal levels of alpha4betadelta expression in the CA1 hippocampus. pirarubicin 100-103 carbonic anhydrase 1 Mus musculus 195-198 31007754-0 2019 Pirarubicin reduces USP22 expression by inhibiting CREB-1 phosphorylation in HeLa cells. pirarubicin 0-11 ubiquitin specific peptidase 22 Homo sapiens 20-25 31007754-0 2019 Pirarubicin reduces USP22 expression by inhibiting CREB-1 phosphorylation in HeLa cells. pirarubicin 0-11 cAMP responsive element binding protein 1 Homo sapiens 51-55 31007754-4 2019 In the current study, treatment with THP induced HeLa cell apoptosis and decreased USP22 expression in a dose- and time-dependent manner. pirarubicin 37-40 ubiquitin specific peptidase 22 Homo sapiens 83-88 31007754-7 2019 Additionally, treatment with THP significantly decreased the phosphorylation of CREB-1 at ser133 in HeLa cells. pirarubicin 29-32 cAMP responsive element binding protein 1 Homo sapiens 80-86 30718548-7 2019 In VTA, 3alpha,5alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor alpha2 subunits (~60%) and MyD88 (~40%). pirarubicin 21-25 TNF receptor-associated factor 6 Mus musculus 64-69 30718548-7 2019 In VTA, 3alpha,5alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor alpha2 subunits (~60%) and MyD88 (~40%). pirarubicin 21-25 mast cell protease 1 Mus musculus 94-99 30718548-7 2019 In VTA, 3alpha,5alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor alpha2 subunits (~60%) and MyD88 (~40%). pirarubicin 21-25 toll-like receptor 4 Mus musculus 126-130 30718548-7 2019 In VTA, 3alpha,5alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor alpha2 subunits (~60%) and MyD88 (~40%). pirarubicin 21-25 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 157-163 30718548-7 2019 In VTA, 3alpha,5alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor alpha2 subunits (~60%) and MyD88 (~40%). pirarubicin 21-25 MYD88, innate immune signal transduction adaptor Rattus norvegicus 184-189 30588188-0 2018 RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. pirarubicin 26-37 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 0-5 30588188-0 2018 RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. pirarubicin 26-37 thymoma viral proto-oncogene 1 Mus musculus 65-68 30588188-0 2018 RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. pirarubicin 26-37 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 69-72 30588188-2 2018 Pirarubicin and pirarubicin-based combination therapies have been demonstrated to be effective against HCC in TACE. pirarubicin 0-11 a disintegrin and metallopeptidase domain 17 Mus musculus 110-114 29715084-5 2018 O2 - derived from pirarubicin in the presence of Cu(II) was detected by cytochrome c reduction. pirarubicin 18-29 cytochrome c, somatic Homo sapiens 72-84 30793486-4 2019 In addition, our findings demonstrated that the proliferation, migration and invasion of hepatocellular carcinoma were suppressed, but the apoptosis was increased, as a result of MARCH1 knockdown by either siRNA targeting MARCH1 or pirarubicin treatment. pirarubicin 232-243 membrane associated ring-CH-type finger 1 Homo sapiens 179-185 30860215-3 2019 Herein we describe new synthetic routes to the THP platform including replacing the 1,6-dimethyl-3-hydroxypyridin-4-one N1-CH3 group of THPMe with O (tris(6-methyl-3-hydroxypyran-4-one, THPO) and N1-H (tris(6-methyl-3-hydroxypyridin-4-one), THPH) groups. pirarubicin 47-50 thrombopoietin Mus musculus 186-190 30588188-2 2018 Pirarubicin and pirarubicin-based combination therapies have been demonstrated to be effective against HCC in TACE. pirarubicin 16-27 a disintegrin and metallopeptidase domain 17 Mus musculus 110-114 30588188-5 2018 Here we found that RIPK1 and p21 may participate in the resistance to pirarubicin. pirarubicin 70-81 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 19-24 30588188-5 2018 Here we found that RIPK1 and p21 may participate in the resistance to pirarubicin. pirarubicin 70-81 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 29-32 30588188-6 2018 In this study, we first found that inhibition of RIPK1 significantly decreased pAKT and increased p21, accompanied by G0/G1 phase cell cycle arrest and cell anti-proliferation in pirarubicin-treated hepatocellular carcinoma cells. pirarubicin 179-190 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 49-54 30588188-7 2018 Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. pirarubicin 170-181 thymoma viral proto-oncogene 1 Mus musculus 29-32 30588188-7 2018 Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. pirarubicin 170-181 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 75-80 30588188-7 2018 Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. pirarubicin 170-181 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 117-122 30588188-7 2018 Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. pirarubicin 170-181 thymoma viral proto-oncogene 1 Mus musculus 123-126 30588188-7 2018 Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. pirarubicin 170-181 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 127-130 30588188-9 2018 Upon exposure to pirarubicin treatment, xenografts under RIPK1 inhibition maintained higher levels of p21 than control xenografts. pirarubicin 17-28 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 57-62 30588188-9 2018 Upon exposure to pirarubicin treatment, xenografts under RIPK1 inhibition maintained higher levels of p21 than control xenografts. pirarubicin 17-28 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 102-105 30588188-10 2018 In conclusion, the results in our study demonstrated that RIPK1 inhibition enhances the anti-tumor effect of pirarubicin by overcoming drug resistance. pirarubicin 109-120 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 58-63 30588188-11 2018 RIPK1 inhibitor might be used as an adjuvant to potentiate the inhibitory effect of pirarubicin against primary hepatocellular carcinoma. pirarubicin 84-95 receptor (TNFRSF)-interacting serine-threonine kinase 1 Mus musculus 0-5 29308527-1 2018 PURPOSE: [68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68Ge/68Ga-generator. pirarubicin 39-42 folate hydrolase 1 Homo sapiens 44-48 29512924-10 2018 On the other hand, down-regulating PKM2 activates AMPK and inhibits STAT3, correlated with THP sensitivity. pirarubicin 91-94 pyruvate kinase M1/2 Homo sapiens 35-39 29512924-10 2018 On the other hand, down-regulating PKM2 activates AMPK and inhibits STAT3, correlated with THP sensitivity. pirarubicin 91-94 signal transducer and activator of transcription 3 Homo sapiens 68-73 28921867-1 2018 A BCL1 leukemia-cell-targeted polymer-drug conjugate with a narrow molecular weight distribution consisting of an N-(2-hydroxypropyl)methacrylamide copolymer carrier and the anticancer drug pirarubicin is prepared by controlled radical copolymerization followed by metal-free click chemistry. pirarubicin 190-201 cyclin D1 Mus musculus 2-6 30125887-0 2018 NOS3 895G&gt;T and CBR3 730G&gt;A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP. pirarubicin 151-154 nitric oxide synthase 3 Homo sapiens 0-4 30125887-10 2018 CONCLUSIONS: Our results suggest that NOS3 895G>T and CBR3 730G>A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. pirarubicin 195-198 nitric oxide synthase 3 Homo sapiens 38-42 28921867-5 2018 Treatment of mice with established BCL1 leukemia using the scFv-targeted polymer conjugate leads to a markedly prolonged survival time of the experimental animals compared with the treatment using the free drug and the nontargeted polymer-pirarubicin conjugate. pirarubicin 239-250 cyclin D1 Mus musculus 35-39 28824057-0 2017 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. pirarubicin 23-27 caspase recruitment domain family member 16 Homo sapiens 28-31 29061786-7 2017 In HP100 cells, THP-induced apoptosis, evaluated by DNA ladder formation, H2O2 generation, mitochondrial membrane potential decrease and caspase-3/7 activity, was suppressed or delayed compared to those of HL-60 cells. pirarubicin 16-19 caspase 3 Homo sapiens 137-146 28661460-2 2017 In this study, we investigated the effects and mechanism of a novel histone deacetylase (HDAC8) inhibitor, (E)-N-hydroxy-4-methoxy-2-(biphenyl-4-yl)cinnamide (WK2-16), on MMP-9 production and activation in stimulated human monocytic THP-1 cells. pirarubicin 233-236 histone deacetylase 8 Homo sapiens 89-94 28666424-8 2017 Significant improvement was noticed after three cycles of chemotherapy of THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone). pirarubicin 83-94 caspase recruitment domain family member 16 Homo sapiens 78-81 28367221-6 2017 Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-beta1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. pirarubicin 171-174 transforming growth factor, beta 1 Rattus norvegicus 199-208 28502307-5 2017 Flow cytometry was done to detect the apoptosis rate of low-DAB2IP-expressing cells treated with pirarubicin. pirarubicin 97-108 DAB2 interacting protein Homo sapiens 60-66 28166203-3 2017 In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy. pirarubicin 129-140 hepatocellular carcinoma up-regulated long non-coding RNA Homo sapiens 168-172 28166203-3 2017 In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy. pirarubicin 142-145 hepatocellular carcinoma up-regulated long non-coding RNA Homo sapiens 168-172 27936775-0 2017 Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. pirarubicin 77-88 interferon gamma inducible protein 47 Mus musculus 67-71 28367221-0 2017 Rutin Protects against Pirarubicin-Induced Cardiotoxicity through TGF-beta1-p38 MAPK Signaling Pathway. pirarubicin 23-34 transforming growth factor, beta 1 Rattus norvegicus 66-75 28367221-6 2017 Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-beta1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. pirarubicin 171-174 caspase 9 Rattus norvegicus 230-239 28367221-6 2017 Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-beta1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. pirarubicin 171-174 caspase 7 Rattus norvegicus 241-250 28367221-6 2017 Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-beta1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. pirarubicin 171-174 caspase 3 Rattus norvegicus 256-265 27121155-0 2016 Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-kappaB-dependent manner. pirarubicin 19-31 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 114-123 28174380-0 2017 [Efficacy and Safety of THP-COP for Diffuse Large B-Cell Lymphoma]. pirarubicin 24-27 caspase recruitment domain family member 16 Homo sapiens 28-31 27744704-6 2016 PAMV6/THP was able to reverse MDR more than free THP in MCF-7/ADR cells, likely reflecting the remarkably higher intracellular THP concentration in micelle-treated cells and PAMV6-mediated inhibition of P-gp activity. pirarubicin 6-9 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 27324234-6 2016 The OCT2 inhibitors, cimetidine and (+)-tetrahydropalmatine ((+)-THP), significantly reduced NC accumulation and cytotoxicity in MDCK-hOCT2, MDCK-hOCT2/hMATE1 and rPCPT cells. pirarubicin 61-68 solute carrier family 22 member 2 Rattus norvegicus 4-8 27324234-6 2016 The OCT2 inhibitors, cimetidine and (+)-tetrahydropalmatine ((+)-THP), significantly reduced NC accumulation and cytotoxicity in MDCK-hOCT2, MDCK-hOCT2/hMATE1 and rPCPT cells. pirarubicin 61-68 POU class 2 homeobox 2 Homo sapiens 134-139 27324234-6 2016 The OCT2 inhibitors, cimetidine and (+)-tetrahydropalmatine ((+)-THP), significantly reduced NC accumulation and cytotoxicity in MDCK-hOCT2, MDCK-hOCT2/hMATE1 and rPCPT cells. pirarubicin 61-68 POU class 2 homeobox 2 Homo sapiens 146-151 27324234-6 2016 The OCT2 inhibitors, cimetidine and (+)-tetrahydropalmatine ((+)-THP), significantly reduced NC accumulation and cytotoxicity in MDCK-hOCT2, MDCK-hOCT2/hMATE1 and rPCPT cells. pirarubicin 61-68 solute carrier family 47 member 1 Homo sapiens 152-158 27097054-0 2016 Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. pirarubicin 98-109 autophagy related 4B cysteine peptidase Homo sapiens 24-29 27097054-6 2016 By scanning the mRNA level change of autophagy-related genes, we found that the upregulation of ATG4B (autophagy-related 4B cysteine peptidase) plays an important role in THP-induced autophagy. pirarubicin 171-174 autophagy related 4B cysteine peptidase Homo sapiens 96-101 27097054-6 2016 By scanning the mRNA level change of autophagy-related genes, we found that the upregulation of ATG4B (autophagy-related 4B cysteine peptidase) plays an important role in THP-induced autophagy. pirarubicin 171-174 autophagy related 4B cysteine peptidase Homo sapiens 103-142 27097054-10 2016 These results for the first time reveal the presence of a MIR34C-5p-ATG4B-autophagy signaling axis in THP-treated cervical cancer cells in vitro and in vivo, and the axis, at least partially, accounts for the THP nonsensitivity in cervical cancer patients. pirarubicin 102-105 autophagy related 4B cysteine peptidase Homo sapiens 68-73 26903543-9 2016 Furthermore, we revealed that treatment with the combination ofl-THP and LDN has an upregulatory effect on both plasmabeta-endorphin and hypothalamic POMC that was not observed inl-THP-treated groups. pirarubicin 64-68 proopiomelanocortin Rattus norvegicus 150-154 28352766-9 2016 After the case was treated by cyclophosphamide pirarubicin vindesine dexamethasone (CHOP) chemotherapy for six courses, her clinical symptoms were partially alleviated, while CT showed progression disease. pirarubicin 47-58 DNA damage inducible transcript 3 Homo sapiens 84-88 26984450-10 2016 CONCLUSION: The absence of any significant changes in GLS and cardiac biomarkers (TnI and BNP) further support the cardiac safety of THP in patients with metastatic HER2-positive breast cancer. pirarubicin 133-136 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 26573232-0 2016 A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. pirarubicin 95-106 WT1 transcription factor Homo sapiens 43-46 26592470-3 2016 We first determined that flumazenil (100 nM-100 muM, IC50=~1 muM) acted as a negative modulator, reducing GABA (10 muM)-gated current in the presence of 100 nM THP (to increase receptor efficacy), assessed with whole cell patch clamp recordings of recombinant alpha4beta2delta expressed in HEK-293 cells. pirarubicin 160-163 latexin Homo sapiens 48-51 26410305-0 2015 DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. pirarubicin 40-51 DAB2 interacting protein Homo sapiens 0-6 26648574-0 2016 Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells. pirarubicin 50-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 77-82 26648574-0 2016 Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells. pirarubicin 50-61 proliferating cell nuclear antigen Homo sapiens 98-102 26648574-6 2016 In addition, the present study demonstrated that activation of TRPV1 enhanced the anti-proliferative effects of pirarubicin using an MTT assay and cell cycle analysis. pirarubicin 112-123 transient receptor potential cation channel subfamily V member 1 Homo sapiens 63-68 26861099-6 2016 She achieved complete remission after six courses of biweekly THP-COP therapy, to which field radiation (39.6 Gy) was added. pirarubicin 62-65 caspase recruitment domain family member 16 Homo sapiens 66-69 26410305-3 2015 Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. pirarubicin 215-226 DAB2 interacting protein Homo sapiens 17-23 26410305-3 2015 Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. pirarubicin 215-226 twist family bHLH transcription factor 1 Homo sapiens 137-143 26410305-3 2015 Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. pirarubicin 215-226 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 26452495-3 2015 We report the properties of a tris(hydroxypyridinone) conjugate of the SSTR2-targeted peptide, Tyr(3)-octreotate (TATE), and compare the (68)Ga-labelling and biodistribution of [(68)Ga(THP-TATE)] with the clinical radiopharmaceutical [(68)Ga(DOTATATE)]. pirarubicin 185-188 somatostatin receptor 2 Mus musculus 71-76 26725355-0 2015 [Langerhans cell sarcoma developing acute myeloid leukemia after achieving complete response by THP-COP]. pirarubicin 96-99 caspase recruitment domain family member 16 Homo sapiens 100-103 26725355-5 2015 However, he developed acute myeloid leukemia (AML) 11 months after completion of the THP-COP therapy, and received only supportive care until his death. pirarubicin 85-88 caspase recruitment domain family member 16 Homo sapiens 89-92 26422373-0 2015 Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers. pirarubicin 15-26 albumin Mus musculus 51-64 26422373-1 2015 In our study, we aimed to develop a codelivery nanoparticulate system of pirarubicin (THP) and paclitaxel (PTX) (Co-AN) using human serum albumin to improve the therapeutic effect and reduce systemic toxicities. pirarubicin 73-84 albumin Mus musculus 132-145 26422373-1 2015 In our study, we aimed to develop a codelivery nanoparticulate system of pirarubicin (THP) and paclitaxel (PTX) (Co-AN) using human serum albumin to improve the therapeutic effect and reduce systemic toxicities. pirarubicin 86-89 albumin Mus musculus 132-145 26256086-8 2015 The effects of chemotherapeutic agents (5-FU and pirarubicin) on GP73 expression were tested in three HCC cell lines (HepG2, HCCLM3 and MHCC97H). pirarubicin 49-60 golgi membrane protein 1 Homo sapiens 65-69 26256086-11 2015 Pirarubicin, not 5-FU, significantly increased GP73 expression in three cell lines. pirarubicin 0-11 golgi membrane protein 1 Homo sapiens 47-51 25791481-10 2015 Pirarubicin-induced autophagy was mediated via the mTOR/p70S6K/4E-BP1 signaling pathway. pirarubicin 0-11 mechanistic target of rapamycin kinase Homo sapiens 51-55 26075716-7 2015 Finally, NaCl treated THP-1 or BV2 cells are inefficient in clearing Abeta when co-cultured with rat primary neurons. pirarubicin 22-25 amyloid beta (A4) precursor protein Mus musculus 69-74 22580740-10 2012 Furthermore, the treatment of MG63/DOX cells with THP (200-1000 ng/mL) downregulated cyclin B1 expression, and decreased the phosphorylated Cdc2 at Thr(161). pirarubicin 50-53 cyclin B1 Homo sapiens 85-94 25591827-7 2015 Similarly, P-gp of pirarubicin was unaffected by Abeta42. pirarubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 25544773-0 2015 Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. pirarubicin 57-68 microRNA 21 Homo sapiens 14-25 25544773-0 2015 Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. pirarubicin 57-68 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 26-29 25544773-3 2015 Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). pirarubicin 136-147 microRNA 21 Homo sapiens 46-57 24778366-6 2014 Quinidine and (+)-tetrahydropalmatine [(+)-THP], OCT1 and OCT3 inhibitors, significantly reduced the uptake of NC in MDCK-hOCT1 cells, MDCK-hOCT3 cells, and rat primary hepatocytes, but only (+)-THP markedly attenuated the NC-induced toxicity. pirarubicin 39-46 solute carrier family 22 member 1 Homo sapiens 122-127 24778366-6 2014 Quinidine and (+)-tetrahydropalmatine [(+)-THP], OCT1 and OCT3 inhibitors, significantly reduced the uptake of NC in MDCK-hOCT1 cells, MDCK-hOCT3 cells, and rat primary hepatocytes, but only (+)-THP markedly attenuated the NC-induced toxicity. pirarubicin 39-46 solute carrier family 22 member 3 Homo sapiens 140-145 24927633-5 2014 HO-1 expression in murine colon cells C26 and human colon cancer cells HT29 and DLD1 under HO-1 inducer hemin and anticancer drug pirarubicin (THP) treatment was examined by RT-PCR, and the cell viability after each treatment was investigated by MTT assay. pirarubicin 130-141 heme oxygenase 1 Mus musculus 0-4 24927633-5 2014 HO-1 expression in murine colon cells C26 and human colon cancer cells HT29 and DLD1 under HO-1 inducer hemin and anticancer drug pirarubicin (THP) treatment was examined by RT-PCR, and the cell viability after each treatment was investigated by MTT assay. pirarubicin 143-146 heme oxygenase 1 Mus musculus 0-4 24927633-10 2014 Moreover, HO-1 expression/induction also related to the chemosensitivity of colon cells; HO inhibitor zinc protoporphyrin significantly increased cytotoxicities of THP (i.e., 2.6 - 5.3 folds compared to cells without zinc protoporphyrin treatment). pirarubicin 164-167 heme oxygenase 1 Homo sapiens 10-14 24716934-1 2014 PURPOSE: To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. pirarubicin 79-90 ADAM metallopeptidase domain 17 Homo sapiens 143-147 23136113-3 2012 The beta-keto phosphonate/aldehyde precursor for the ring-closure reaction was obtained by esterification of a omega-diethylphosphono carboxylic acid fragment and a secondary alcohol fragment incorporating the THP ring that is embedded in the macrocyclic core structure of 1 and ent-2. pirarubicin 210-213 solute carrier family 29 member 2 Homo sapiens 279-284 24519501-0 2015 Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. pirarubicin 9-12 caspase recruitment domain family member 16 Homo sapiens 13-16 24519501-7 2015 All patients received six cycles of biweekly THP-COP. pirarubicin 45-48 caspase recruitment domain family member 16 Homo sapiens 49-52 24519501-14 2015 Biweekly THP-COP is a safe and promising therapy for patients with newly diagnosed PTCL. pirarubicin 9-12 caspase recruitment domain family member 16 Homo sapiens 13-16 23999061-4 2014 In human monocytes (THP-1 cells) the ASAP2 gene is more weakly expressed but more and faster inducible by the biologically active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), than in M2-type macrophages (phorbol ester-differentiated THP-1 cells). pirarubicin 20-23 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 Homo sapiens 37-42 23245571-7 2013 The results of both pirarubicin uptake and the cytotoxicity assay, indicate that the new compounds of the series are potent P-gp-mediated MDR reversers. pirarubicin 20-31 phosphoglycolate phosphatase Homo sapiens 124-128 22580740-10 2012 Furthermore, the treatment of MG63/DOX cells with THP (200-1000 ng/mL) downregulated cyclin B1 expression, and decreased the phosphorylated Cdc2 at Thr(161). pirarubicin 50-53 cyclin dependent kinase 1 Homo sapiens 140-144 21298773-11 2011 The cumulative dose of THP was significantly correlated with BNP levels after exercise (r = 0.27, P = 0.03), but not with any other cardiac measurements. pirarubicin 23-26 natriuretic peptide B Homo sapiens 61-64 22198116-0 2012 Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells. pirarubicin 46-57 caspase 3 Homo sapiens 91-100 22198116-0 2012 Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells. pirarubicin 46-57 caspase 8 Homo sapiens 101-110 22198116-0 2012 Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells. pirarubicin 46-57 nuclear paraspeckle assembly transcript 1 Homo sapiens 178-182 22205156-6 2012 Epirubicin and pirarubicin significantly increased the TRAIL-R2 expression at both the mRNA and the protein levels. pirarubicin 15-26 TNF receptor superfamily member 10b Homo sapiens 55-63 21438831-1 2011 The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. pirarubicin 23-34 uromodulin Homo sapiens 66-69 20089670-8 2010 The A2A agonist increases apoA-I-mediated cholesterol efflux nearly twofold in THP-1-derived macrophages (from 9.5% to 17.5+2.5% [3H]-cholesterol efflux; P<0.0090 vs. control; n=3) but not in ABCA1 KD cells. pirarubicin 79-82 apolipoprotein A1 Homo sapiens 26-32 21160270-0 2010 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. pirarubicin 90-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 21160270-0 2010 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. pirarubicin 90-101 nuclear factor I C Homo sapiens 59-62 21160270-0 2010 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. pirarubicin 103-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 21160270-0 2010 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. pirarubicin 103-109 nuclear factor I C Homo sapiens 59-62 20515395-1 2010 BACKGROUND: Pirarubicin (THP), an analogue of doxorubicin, has exhibited promising activities against acute leukemia, malignant lymphoma, and several solid tumors. pirarubicin 12-23 uromodulin Mus musculus 25-28 20497650-1 2010 OBJECTIVE: To investigate whether neuroblastoma cells LA-N-6 express Foxp3 and whether the expression of Foxp3 is sensitive to chemotherapy by cyclophosvnamide (CTX)and pirarubicin (THP). pirarubicin 169-180 forkhead box P3 Homo sapiens 105-110 20497650-1 2010 OBJECTIVE: To investigate whether neuroblastoma cells LA-N-6 express Foxp3 and whether the expression of Foxp3 is sensitive to chemotherapy by cyclophosvnamide (CTX)and pirarubicin (THP). pirarubicin 182-185 forkhead box P3 Homo sapiens 105-110 20497650-4 2010 The effects of CTX and THP on Foxp3 expression were examined by flow cytometry and real-time PCR assays. pirarubicin 23-26 forkhead box P3 Homo sapiens 30-35 20497650-6 2010 At sub-optimal concentration, chemotherapy drugs CTX and THP significantly down-regulated expression of Foxp3 on LA-N-6 cells at protein level (P<0.05). pirarubicin 57-60 forkhead box P3 Homo sapiens 104-109 20497650-8 2010 CONCLSUSIONS: Neuroblastoma cells LA-N-6 express Foxp3 at a high level, which can be suppressed by chemotherapy drugs CTX and THP. pirarubicin 126-129 forkhead box P3 Homo sapiens 49-54 20618418-4 2010 Furthermore, both chronic administration of THP and its withdrawal transiently increase expression of the alpha4 subunit of the GABAA receptor in the brain. pirarubicin 44-47 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1 Mus musculus 128-133 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 115-126 BCL2 associated X, apoptosis regulator Homo sapiens 137-140 20104851-5 2010 Compound 9 shows the most promising properties as it was able to nearly completely reverse Pgp-dependent pirarubicin extrusion at nanomolar doses and increased the cytotoxicity of doxorubicin with a reversal fold (RF) of 19.1 at 3 microM dose. pirarubicin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 20357441-8 2010 Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression. pirarubicin 28-39 proliferating cell nuclear antigen Homo sapiens 69-84 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 224-235 BCL2 apoptosis regulator Homo sapiens 131-136 20357441-8 2010 Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression. pirarubicin 28-39 BCL2 apoptosis regulator Homo sapiens 99-104 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 224-235 BCL2 associated X, apoptosis regulator Homo sapiens 137-140 20357441-8 2010 Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression. pirarubicin 28-39 BCL2 associated X, apoptosis regulator Homo sapiens 120-123 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 115-126 BCL2 apoptosis regulator Homo sapiens 131-136 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 apoptosis regulator Homo sapiens 29-34 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 associated X, apoptosis regulator Homo sapiens 39-42 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 apoptosis regulator Homo sapiens 65-70 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 associated X, apoptosis regulator Homo sapiens 71-74